Author:
Sergina Natalia V.,Rausch Megan,Wang Donghui,Blair Jimmy,Hann Byron,Shokat Kevan M.,Moasser Mark M.
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Winer, E. P. et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (Erlotinib HCl, OSI-774) in women with previously treated, locally advanced or metastatic breast cancer. Breast Cancer Res. Treatm. 76 (suppl. 1), abstr. 445. (2002)
2. Blackwell, K. et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 23, abstr. 3006. (2004)
3. Dees, E. C. et al. Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. Proc. Am. Soc. Clin. Oncol. 23, abstr. 3188. (2004)
4. Campos, S. M. et al. A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Proc. Am. Soc. Clin. Oncol. 23, abstr. 5054. (2004)
5. Baselga, J. et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 23, 5323–5333 (2005)
Cited by
826 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献